Anu Thummala

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, John Crown, István Láng et al. · The Lancet Oncology · 2014 · 1.9K citations

Cyclin-dependent Kinase 4/6, Breast Oncology, Inhibitor Palbociclib +11

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Richard S. Finn, Katalin Boér, Igor Bondarenko et al. · Breast Cancer Research and Treatment · 2020 · 164 citations · Full text

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

Antoinette R. Tan, Gail S. Wright, Anu Thummala et al. · The Lancet Oncology · 2019 · 111 citations

Chemotherapy Versus Chemotherapy, Breast Oncology, Medicine +7

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18).

Richard S. Finn, John Crown, István Láng et al. · Journal of Clinical Oncology · 2017 · 67 citations

Part 1, Breast Oncology, Medicine +13

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

Richard S. Finn, John Crown, István Láng et al. · Cancer Research · 2014 · 51 citations

Tumor Biology, Part 1, Oncology +13